<DOC>
	<DOC>NCT02537470</DOC>
	<brief_summary>This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of a biphasic formulation of remogliflozin etabonate compared to placebo, administered over 12 weeks in subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Able to provide written informed consent Subject with clinical diagnosis of type 2 diabetes HbA1c 7.0 10.5% inclusive at Visit 1. History of metabolic acidosis or ketoacidosis. Current active renal disease that is not related to hypertension or type 2 diabetes (e.g. nondiabetic glomerulonephritis, interstitial nephritis, symptomatic nephrolithiasis, etc.) Use of an investigational device or investigational drug within 30 days or 5 halflives (whichever is longer) prior to Visit 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>